Kent Hawryluk

Chief Business Officer

P. Kent Hawryluk has 25 years’ experience as an entrepreneur. He has started and managed more than 10 companies in the media, software and life science industries. Mr. Hawryluk is one of our co-founders and has served as our Chief Business Officer since January 2013. He was Co Founder of MB2 LLC, a clinical stage company focused on diabetes and obesity, and served as its Chief Executive Officer from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, Mr. Hawryluk co founded Marcadia Biotech Inc, and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia was acquired by Roche in December 2010. He currently serves as partner of Twilight Venture Partners, LLC, a private seed and early stage life science venture capital fund, and as a director of Gemphire Therapeutics Inc., a public clinical-stage cardiovascular drug company. Mr. Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg School of Management at Northwestern University, and an M.S. degree in biology from Indiana University Purdue University Indianapolis.